Clinical Trial

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 18, 2024 (before its estimated December 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
Study to assess the effectiveness and safety of SHR 1316, bevacizumab combined with cisplatin/carboplatin for treatment of triple-negative breast cancer brain metastases.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04303988
Lead Sponsor Fudan University
Conditions Breast Cancer
Enrollment 35 participants
Start Date 2020-03-30
Primary Completion 2024-12-30 (estimated)
Study Completion 2025-05-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-18